Bulk Inquiry
SCR7 pyrazine
Axon 2531
CAS:
14892-97-8
Purity:
99%
- Soluble in DMSO
- MF: C18H12N4OS
- MW: 332.38
Description
SCR7 pyrazine is a pyrazine analog of SCR7 reported to inhibit DNA ligase IV-mediated non-homologous end joining (NHEJ). It has been used to increase homology-directed repair outcomes in genome-editing workflows.
DNA ligase IV is essential for canonical NHEJ repair of double-strand breaks. SCR7 pyrazine is useful for studying DNA repair pathway choice and CRISPR/Cas9 editing enhancement, although results should be interpreted with assay-specific controls because SCR7 activity has shown context dependence.
Key Features
- Reported DNA ligase IV/NHEJ inhibitor
- Modulates double-strand break repair pathway choice
- Used to enhance homology-directed repair in CRISPR workflows
- Useful for DNA repair pharmacology with appropriate controls
Applications
- NHEJ and DNA repair pathway studies
- CRISPR/Cas9 genome editing optimization
- Homology-directed repair assays
- DNA ligase IV pharmacology
More Information
| Parent CAS No. | 14892-97-8 |
|---|---|
| Chemical Name | 6,7-diphenyl-2-thioxo-2,3-dihydropteridin-4(1H)-one |
| SMILES | N1C2C(=NC(C3=CC=CC=C3)=C(C3=CC=CC=C3)N=2)C(=O)NC1=S |
| MFCD | N.A. |
| InChi | InChI=1S/C18H12N4OS/c23-17-15-16(21-18(24)22-17)20-14(12-9-5-2-6-10-12)13(19-15)11-7-3-1-4-8-11/h1-10H,(H2,20,21,22,23,24) |
| InChiKey | GSRTWXVBHGOUBU-UHFFFAOYSA-N |
| CID | 10688007 |
| Short Description | NHEJ inhibitor |
References
- T Maruyama et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol. 2015 May;33(5):538-42.
- VT Chu et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol. 2015 May;33(5):543-8.
- M Srivastava et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151(7):1474-87.
Other Categories
Get a Quote for
Loading...